At Shortwave Life Sciences, we’re driven by a focused and experienced leadership team with a wealth of knowledge in drug development, clinical research and strategy, particularly within the psychedelic field. Our first clinical program hones in on addressing anorexia nervosa, a life-threatening condition with no FDA-approved medication, where psilocybin shows promise as a breakthrough therapy. Leveraging established global partnerships across IP, drug development, market intelligence and investor relations, we’re poised to make significant strides in addressing unmet patient needs.

Rooted in the Israeli innovation ecosystem, our IP-driven approach capitalizes on unmatched knowledge and expertise. Through a strategic economic model combining in-house capabilities and strategic partnerships, we’ve optimized our drug discovery and development process to preserve capital and maximize efficiency. With a focus on our current programs and the addition of new IP opportunities, our team is dedicated to leveraging our unique platform to identify, operate, and create value from early-stage, breakthrough initiatives in the treatment of eating disorders and mental health.